ERAS ▼ -12.2% - Erasca, Inc. $ERAS - Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015 20-NOV-2026 07:00 AM ET